• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LI Xiaofang, REN Longfei, WANG Dandan, LI Yuyan. Research progress of anti-Alzheimer′s disease drugs targeting Aβ oligomers[J]. Journal of China Pharmaceutical University, 2021, 52(4): 398-409. DOI: 10.11665/j.issn.1000-5048.20210402
Citation: LI Xiaofang, REN Longfei, WANG Dandan, LI Yuyan. Research progress of anti-Alzheimer′s disease drugs targeting Aβ oligomers[J]. Journal of China Pharmaceutical University, 2021, 52(4): 398-409. DOI: 10.11665/j.issn.1000-5048.20210402
shu

Research progress of anti-Alzheimer′s disease drugs targeting Aβ oligomers

  • Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China

Funds: This study was supported by the Natural Science Foundation of Jiangsu Province (No. BK20191320)
More Information
  • Received Date: April 18, 2021
  • Revised Date: June 24, 2021
    Graphical Abstract
    • Abstract
  • Alzheimer''s disease (AD) is the most common cause of senile dementia, accounting for an estimated 60% to 80% of cases, but there are no approved drugs to slow or stop the progressive clinical decline in the past years.Amyloid cascade hypothesis is recognized as the major etiologic basis for AD, however, the failures of several amyloid plaque-targeted programs have led many to dismiss the amyloid beta (Aβ) hypothesis of AD. Several reports show that soluble oligomers of Aβ (AβOs), which appear in brains more than 10 years before the clinical syndrome, are more toxic than Aβ plaque, causing synaptic dysfunction and neuronal apoptosis. Some agents that can effectively inhibit Aβ oligomer formation or block their toxicity made significant efficacy in clinical 2 and 3 trials, with the potential to be approved for the treatment of AD. This article reviews the recent development of AD drugs targeting Aβ oligomers, analyzes their structural characteristics, mechanism of action, preclinical and clinical data, and discusses the future direction of AD treatment, thus providing new strategies for AD drug research.
    • FullText(HTML)
    • References (64)
  • [1]
    . J China Pharm Univ （中国药科大学学报），2018，49（1）：10-19.
    [2]
    Jia LF，Quan M，Fu Y，et al. Dementia in China： epidemiology，clinical management，and research advances［J］. Lancet Neurol，2020，19（1）：81-92.
    [3]
    Tolar M，Abushakra S，Sabbagh M. The path forward in Alzheimer′s disease therapeutics： reevaluating the amyloid cascade hypothesis［J］. Alzheimers Dement，2020，16（11）：1553-1560.
    [4]
    Chen GF，Xu TH，Yan Y，et al. Amyloid beta： structure，biology and structure-based therapeutic development［J］. Acta Pharmacol Sin，2017，38（9）：1205-1235.
    [5]
    Liu Y，Nguyen M，Robert A，et al. Metal ions in Alzheimer′s disease： a key role or not［J］ ？ Acc Chem Res，2019，52（7）：2026-2035.
    [6]
    Bateman RJ，Aisen PS，De Strooper B，et al. Autosomal-dominant Alzheimer′s disease： a review and proposal for the prevention of Alzheimer′s disease［J］. Alzheimers Res Ther，2011，3（1）：1.
    [7]
    Saddiki H，Fayosse A，Cognat E，et al. Age and the association between apolipoprotein E genotype and Alzheimer disease： a cerebrospinal fluid biomarker-based case-control study［J/OL］. PLoS Med，2020，17（8）：e1003289.
    [8]
    Tolar M，Abushakra S，Hey JA，et al. Aducanumab，gantenerumab，BAN2401，and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer′s disease with potential for near term approval［J］. Alzheimers Res Ther，2020，12（1）：183-206.
    [9]
    Sengupta U，Nilson AN，Kayed R. The role of amyloid-beta oligomers in toxicity，popagation，and immunotherapy［J］. EBioMed，2016，6：42-49.
    [10]
    Lee SJC，Nam E，Lee HJ，et al. Towards an understanding of amyloid-beta oligomers： characterization，toxicity mechanisms，and inhibitors［J］. Chem Soc Rev，2017，46（2）：310-323.
    [11]
    Hoshi M. Multi-angle development of therapeutic methods for Alzheimer′s disease［J］. Br J Pharmacol，2021，178（4）：770-783.
    [12]
    Tomiyama T，Nagata T，Shimada H，et al. A new amyloid beta variant favoring oligomerization in Alzheimer′s-type dementia［J］. Ann Neurol，2008，63（3）：377-387.
    [13]
    Nilsberth C，Westlind-Danielsson A，Eckman CB，et al. The ''arctic'' APP mutation （E693G） causes Alzheimer''s disease by enhanced Abeta protofibril formation［J］. Nat Neurosci，2001，4（9）：887-893.
    [14]
    Sch?ll M，Wall A，Thordardottir S，et al. Low PiB PET retention in presence of pathologic CSF biomarkers in arctic APP mutation carriers［J］. Neurology，2012，79（3）：229-236.
    [15]
    Ahmed M，Davis J，Aucoin D，et al. Structural conversion of neurotoxic amyloid-beta（1-42） oligomers to fibrils［J］. Nat Struct Mol Biol，2010，17（5）：561-567.
    [16]
    Yang J，Zhu BY，Yin W，et al. Differentiating Aβ40 and Aβ42 in amyloid plaques with a small molecule fluorescence probe［J］. Chem Sci，2020，11（20）：5238-5245.
    [17]
    Kocis P，Tolar M，Yu J，et al. Elucidating the Aβ42 anti-aggregation mechanism of action of tramiprosate in Alzheimer′s disease： integrating molecular analytical methods，pharmacokinetic and clinical data［J］. CNS Drugs，2017，31（6）：495-509.
    [18]
    Abushakra S，Porsteinsson A，Scheltens P，et al. Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer′s disease suggest disease modification potential［J］. J Prev Alzheimers Dis，2017，4（3）：149-156.
    [19]
    Hey JA，Kocis P，Hort J，et al. Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits Abeta amyloid oligomer formation in the human brain［J］. CNS Drugs，2018，32（9）：849-861.
    [20]
    Hey JA，Yu JY，Versavel M，et al. Clinical pharmacokinetics and safety of ALZ-801，a novel prodrug of tramiprosate in development for the treatment of Alzheimer′s disease［J］.Clin Pharmacokinet，2018，57（3）：315-333.
    [21]
    Wen G，Chen D，Qin W，et al. Stabilizing amyloid-β peptide by the N-terminus capture is capable of preventing and eliminating amyloid-β oligomers［J］. Chem Commun （Camb），2017，53（54）：7673-7676.
    [22]
    Miller Y，Ma B，Nussinov R. Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape［J］. Chem Rev，2010，110（8）：4820-4838.
    [23]
    Lee DL，Hodges RS. Structure-activity relationships of de novo designed cyclic antimicrobial peptides based on gramicidin S［J］. Biopolymers，2003，71（1）：28-48.
    [24]
    Andreetto E，Yan LM，Tatarek-Nossol M，et al. Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross- and self-association［J］. Angew Chem Int Ed Engl，2010，49（17）：3081-3085.
    [25]
    Kumar S，Birol M，Miranker AD. Foldamer scaffolds suggest distinct structures are associated with alternative gains-of-function in a preamyloid toxin［J］. Chem Commun （Camb），2016，52（38）：6391-6394.
    [26]
    Kumar S，Henning-Knechtel A，Chehade I，et al. Foldamer-mediated structural rearrangement attenuates Aβ oligomerization and cytotoxicity［J］. J Am Chem Soc，2017，139（47）：17098-17108.
    [27]
    Jiang YX，Jiang XH，Shi XD，et al. α-Helical motif as inhibitors of toxic amyloid-β oligomer generation via highly specific recognition of amyloid surface［J］. iScience，2019，17：87-100.
    [28]
    T?rnquist M，Michaels TCT，Sanagavarapu K，et al. Secondary nucleation in amyloid formation［J］. Chem Commun （Camb），2018，54（63）：8667-8684.
    [29]
    Jiang XH，Cao Y，Han W. In silico study of recognition between Aβ（40） and Aβ（40） fibril surfaces： an N-terminal helical recognition motif and its implications for inhibitor design［J］. ACS Chem Neurosci，2018，9（5）：935-944.
    [30]
    Jiang YH，Deng QW，Zhao H，et al. Development of stabilized peptide-based PROTACs against estrogen receptor α［J］. ACS Chem Biol，2018，13（3）：628-635.
    [31]
    Civitelli L，Sandin L，Nelson E，et al. The luminescent oligothiophene p-FTAA converts toxic Aβ1-42 species into nontoxic amyloid fibers with altered properties［J］. J Biol Chem，2016，291（17）：9233-9243.
    [32]
    Yang SG，Liu W，Lu S，et al. A novel multifunctional compound camellikaempferoside B decreases Aβ production，interferes with Aβ aggregation，and prohibits Aβ-mediated neurotoxicity and neuroinflammation［J］. ACS Chem Neurosci，2016，7（4）：505-518.
    [33]
    Wang XP，Zhang JH，Wang YJ，et al. Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers［J］. FEBS Lett，2009，583（3）：579-584.
    [34]
    Kayed R，Head E，Sarsoza F，et al. Fibril specific，conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers［J］. Mol Neurodegener，2007，2（9）：1-26.
    [35]
    Zhang JX，Lai YH，Mi PY，et al. Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of β-amyloid peptide［J］. Alzheimers Res Ther，2019，11（1）：184-185.
    [36]
    Klein AN，Ziehm T，Tusche M，et al. Optimization of the all-d peptide D3 for Abeta oligomer elimination［J］. PLoS One，2016，11（4）：e0153035.
    [37]
    Liu H，Qian CY，Yang T，et al. Small molecule-mediated co-assembly of amyloid-β oligomers reduces neurotoxicity through promoting non-fibrillar aggregation［J］. Chem Sci，2020，11（27）：7158-7169.
    [38]
    Raymond DM，Nilsson BL. Multicomponent peptide assemblies［J］. Chem Soc Rev，2018，47（10）：3659-3720.
    [39]
    Lantz KA，Hart SG，Planey SL，et al. Inhibition of PTP1B by trodusquemine （MSI-1436） causes fat-specific weight loss in diet-induced obese mice［J］. Obesity （Silver Spring），2010，18（8）：1516-1523.
    [40]
    Zasloff M，Adams AP，Beckerman B，et al. Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential［J］. Proc Natl Acad Sci U S A，2011，108（38）：15978-15983.
    [41]
    Limbocker R，Chia S，Ruggeri FS，et al. Trodusquemine enhances Aβ（42） aggregation but suppresses its toxicity by displacing oligomers from cell membranes［J］. Nat Commun，2019，10（1）：225.
    [42]
    Liu FF，Zhao WP，Zhao F，et al. Dual effect of the acidic polysaccharose ulvan on the inhibition of amyloid-beta protein fibrillation and disintegration of mature fibrils［J］. ACS Appl Mater Interfaces，2020，12（37）：41167-41176.
    [43]
    Uddin MS，Kabir MT，Rahman MS，et al. Revisiting the amyloid cascade hypothesis： from anti-Aβ therapeutics to auspicious new ways for Alzheimer′s disease［J］. Int J Mol Sci，2020，21（16）：5858.
    [44]
    Logovinsky V，Satlin A，Lai R，et al. Safety and tolerability of BAN2401 — a clinical study in Alzheimer′s disease with a protofibril selective Aβ antibody［J］. Alzheimers Res Ther，2016，8（1）：14.
    [45]
    Englund H，Sehlin D，Johansson AS，et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples［J］. J Neurochem，2007，103（1）：334-345.
    [46]
    S?llvander S，Nikitidou E，Gallasch L，et al. The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death［J］. J Neuroinflammation，2018，15（1）：98.
    [47]
    Lord A，Gumucio A，Englund H，et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer′s disease［J］. Neurobiol Dis，2009，36（3）：425-434.
    [48]
    Abbasi J. Promising results in 18-month analysis of Alzheimer drug candidate［J］. JAMA，2018，320（10）：965-965.
    [49]
    Meilandt WJ，Maloney JA，Imperio J，et al. Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ［J］. Alzheimers Res Ther，2019，11（1）：97.
    [50]
    Ultsch M，Li B，Maurer T，et al. Structure of crenezumab complex with Aβ shows loss of β-hairpin［J］. Sci Rep，2016，6（1）：39374.
    [51]
    Adolfsson O，Pihlgren M，Toni N，et al. An effector-reduced anti-β-amyloid （Aβ） antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ［J］. J Neurosci，2012，32（28）：9677-9689.
    [52]
    Cummings JL，Cohen S，Van Dyck CH，et al. ABBY： A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease［J/OL］. Neurology，2018，90（21）：e1889-1897.
    [53]
    Salloway S，Honigberg LA，Cho W，et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind，placebo-controlled，randomized phase II study in mild-to-moderate Alzheimer′s disease （BLAZE）［J］. Alzheimers Res Ther，2018，10（1）：96.
    [54]
    Rios-Romenets S，Lopera F，Sink KM，et al. Baseline demographic，clinical，and cognitive characteristics of the Alzheimer′s prevention initiative （API） autosomal-dominant Alzheimer′s disease colombia trial［J］. Alzheimers Dement，2020，16（7）：1023-1030.
    [55]
    Wiesehan K，Buder K，Linke RP，et al. Selection of d-amino-acid peptides that bind to Alzheimer′s disease amyloid peptide abeta1-42 by mirror image phage display［J］. ChemBioChem，2003，4（8）：748-753.
    [56]
    Van Groen T，Schemmert S，Brener O，et al. The Aβ oligomer eliminating d-enantiomeric peptide RD2 improves cognition without changing plaque pathology［J］. Sci Rep，2017，7（1）：16275.
    [57]
    Leithold LH，Jiang N，Post J，et al. Pharmacokinetic properties of a novel d-peptide developed to be therapeutically active against toxic β-amyloid oligomers［J］. Pharm Res，2016，33（2）：328-336.
    [58]
    Elfgen A，Hupert M，Bochinsky K，et al. Metabolic resistance of the d-peptide RD2 developed for direct elimination of amyloid-β oligomers［J］. Sci Rep，2019，9（1）：1-13.
    [59]
    Zhang T，Gering I，Kutzsche J，et al. Toward the mode of action of the clinical stage all-d-enantiomeric peptide RD2 on Aβ42 aggregation［J］. ACS Chem Neurosci，2019，10（12）：4800-4809.
    [60]
    Olubiyi OO，Frenzel D，Bartnik D，et al. Amyloid aggregation inhibitory mechanism of arginine-rich d-peptides［J］. Curr Med Chem，2014，21（12）：1448-1457.
    [61]
    Umeda T，Ono K，Sakai A，et al. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers［J］. Brain，2016，139（5）：1568-1586.
    [62]
    Cho YS，Mcquade T，Zhang HB，et al. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation［J］. PLoS One，2011，6（8）：e23209.
    [63]
    Li JX，Mcquade T，Siemer AB，et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis［J］ . Cell，2012，150（2）：339-350.
    [64]
    Yang SH，Lee DK，Shin J，et al. Nec-1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice［J］. EMBO Mol Med，2017，9（1）：61-77.
    • Related Articles

  • Related Articles

    [1]ZHU Song, JIANG Jing, LIU Yang, ZOU Wenyu, HU Pengwei, LU Yuting, SONG Min, HANG Taijun. Structural identification of the related substances of lorazepam tablets by LC-MS[J]. Journal of China Pharmaceutical University, 2021, 52(5): 555-565. DOI: 10.11665/j.issn.1000-5048.20210507
    [2]LIANG Fangmei, NI Yueling, WANG Lu, HANG Taijun, SONG Min. Structural identification of the related substances of fusidic acid by LC-MS[J]. Journal of China Pharmaceutical University, 2018, 49(3): 322-332. DOI: 10.11665/j.issn.1000-5048.20180311
    [3]YIN Xiaoya, WANG Cheng, MING Guojun, HANG Taijun. Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques[J]. Journal of China Pharmaceutical University, 2017, 48(6): 701-710. DOI: 10.11665/j.issn.1000-5048.20170611
    [4]FANG Daqing, LIU Fang, ZHANG Sijia, CAI Chaoqun, LIU Minzhuo, LIU Jinghan, YANG Chunhua, WANG Hao. One new diterpenoid alkaloid from Aconitum carmichaeli[J]. Journal of China Pharmaceutical University, 2017, 48(5): 568-571. DOI: 10.11665/j.issn.1000-5048.20170510
    [5]CHEN Wenhua, ZOU Limin, ZHANG Fei, ZHANG Liandi, LIAO Mingyi, DING Li. Identification of the related substances in bendamustine hydrochloride[J]. Journal of China Pharmaceutical University, 2015, 46(3): 333-338. DOI: 10.11665/j.issn.1000-5048.20150312
    [6]ZHOU Yongmei, SHI Xianming, MA Lei, ZHANG Sifang. Isolation and identification of Withaphysalins from Physalis minima[J]. Journal of China Pharmaceutical University, 2015, 46(1): 62-65. DOI: 10.11665/j.issn.1000-5048.20150107
    [7]RAO Ya-kun, DING Li, YU Yong. Structural identification of two major impurities in sodium levofolinate[J]. Journal of China Pharmaceutical University, 2012, 43(4): 350-354.
    [8]WANG Ying, YIN Hong-ping, CHEN Tao, WANG Min. Preliminary structural identification and protection on renal cell injury of acidic polysaccharide from Cordyceps sinensis[J]. Journal of China Pharmaceutical University, 2009, 40(6): 559-564.
    [9]Isolation and Identification of Two Taxane DiterpenoidCompounds[J]. Journal of China Pharmaceutical University, 2001, (3): 32-34.
    [10]Studies on 1H NMR of Naturally Occurring Taxane Diterpenoids and Revising Suggestions on Some Structures[J]. Journal of China Pharmaceutical University, 1998, (4): 19-22+25.

Catalog

    Get Citation
    PDF
    XML
    Article views (451) PDF downloads (777) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：295154

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return